Northland Securities Estimates Brainsway Q1 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities researchers at Northland Securities lowered their Q1 2026 EPS estimates for Brainsway in a research note issued to investors on Wednesday, March 11th. Northland Securities analyst C. Byrnes now forecasts that the company will post earnings per share of $0.03 for the quarter, down from their previous estimate of $0.04. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share.

Several other analysts have also issued reports on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Brainsway in a report on Monday, December 29th. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, HC Wainwright reduced their price objective on shares of Brainsway from $30.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Brainsway presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Brainsway Price Performance

Brainsway stock opened at $13.74 on Thursday. The firm has a market cap of $538.88 million, a PE ratio of 54.96 and a beta of 1.20. The stock’s fifty day moving average price is $12.04 and its two-hundred day moving average price is $9.48. Brainsway has a one year low of $3.92 and a one year high of $14.65.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings results on Wednesday, March 11th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. The business had revenue of $14.55 million during the quarter, compared to analysts’ expectations of $14.02 million. Brainsway had a return on equity of 11.34% and a net margin of 14.62%.

Hedge Funds Weigh In On Brainsway

A number of institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new stake in Brainsway in the second quarter valued at about $85,000. Bank of America Corp DE bought a new position in shares of Brainsway in the third quarter worth about $107,000. Royal Bank of Canada lifted its holdings in shares of Brainsway by 1,145.9% in the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after acquiring an additional 7,735 shares during the last quarter. Centiva Capital LP acquired a new stake in shares of Brainsway in the 3rd quarter valued at approximately $181,000. Finally, NewEdge Advisors LLC boosted its stake in shares of Brainsway by 61.5% in the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after purchasing an additional 7,549 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

Key Brainsway News

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Q4 beat — Brainsway reported $0.14 EPS and $14.6M revenue, topping consensus and showing healthy margin/ROE metrics; management highlighted operational momentum in the quarter. MarketBeat: Q4 results & transcript
• Positive Sentiment: Q4 revenue growth and operational update — company said Q4 revenue grew ~27% and exceeded prior guidance, which underpinned optimism and drove price strength after the print. TheMarketIsOpen: Q4 momentum
• Neutral Sentiment: Earnings materials available — the full Q4/FY2025 results, earnings call transcript and press materials were published (useful for deeper due diligence). Yahoo Finance: Q4 earnings call transcript
• Neutral Sentiment: Reported short-interest data in March appears inconsistent/zero in public feeds (0 shares / NaN changes) — does not provide a clear short-squeeze signal. (No reliable link available.)
• Negative Sentiment: Weaker FY2026 guidance — management guided revenue to $51.0M–$52.0M versus consensus ~ $65M, which is the primary negative catalyst pressuring the stock despite the quarter beat. Benzinga: Q4 beat, guidance below estimates
• Negative Sentiment: Analyst actions — HC Wainwright cut its price target from $30 to $15 (still a Buy), and Northland trimmed its Q1 EPS estimate modestly (from $0.04 to $0.03), which reduces near-term upside expectations. Benzinga: PT change MarketBeat: Analyst note

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.